DeepMed Research

MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

Assessing Choice in the Employer Setting (ACES) Study

Completed

Conditions: Healthy

Interventions: Biological: Control - Usual care offering TIV only with baseline advertisement
Biological: Choice of TIV or FluMist with baseline advertisement
Other: Choice of TIV or FluMist with enhanced advertisement and incentives

First Posted Date: 2008-12-16

Last Posted Date: 2013-11-20

Lead Sponsor: MedImmune LLC

Target Recruit Count: 4411

Registration Number: NCT00808808

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

Phase 1

Completed

Conditions: Kidney Diseases

Interventions: Drug: MEDI-507

First Posted Date: 2008-12-12

Last Posted Date: 2008-12-12

Lead Sponsor: MedImmune LLC

Target Recruit Count: 13

Registration Number: NCT00807794

Locations: 🇺🇸
San Antonio Community Hospital, San Antonio, Texas, United States
🇺🇸
Indiana University, Bloomington, Indiana, United States
🇺🇸
University of Virginia, Charlottesville,, Virginia, United States

and more 1 locations

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

Phase 1

Completed

Conditions: Cancer
Graft-Versus-Host Disease

Interventions: Drug: MEDI-507

First Posted Date: 2008-12-11

Last Posted Date: 2008-12-11

Lead Sponsor: MedImmune LLC

Target Recruit Count: 17

Registration Number: NCT00806728

Locations: 🇺🇸
University Hospital-University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
🇺🇸
Western Pennsylvania Hospital - Western Pennsylvania Cancer Center, Pittsburgh, Pennsylvania, United States

and more 7 locations

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

Phase 1

Completed

Conditions: Graft-Versus-Host Disease

Interventions: Drug: MEDI-507
Other: Placebo

First Posted Date: 2008-12-10

Last Posted Date: 2008-12-11

Lead Sponsor: MedImmune LLC

Target Recruit Count: 34

Registration Number: NCT00806208

Locations: 🇺🇸
Baylor Institute of Transplant Sciences, Dallas, Texas, United States
🇺🇸
Washington University Medical Center, St. Louis, Missouri, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: MEDI-547

First Posted Date: 2008-11-24

Last Posted Date: 2011-11-17

Lead Sponsor: MedImmune LLC

Target Recruit Count: 6

Registration Number: NCT00796055

Locations: 🇺🇸
Research Site, Detroit, Michigan, United States

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Other: Placebo
Biological: Benralizumab 100 mg
Biological: Benralizumab 25 mg
Biological: Benralizumab 200 mg

First Posted Date: 2008-10-31

Last Posted Date: 2019-12-27

Lead Sponsor: MedImmune LLC

Target Recruit Count: 35

Registration Number: NCT00783289

Locations: 🇺🇸
Allergy Associates Research Center, Portland, Oregon, United States
🇺🇸
Research Site, Upland, Pennsylvania, United States

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: MEDI-559
Other: Placebo

First Posted Date: 2008-10-07

Last Posted Date: 2016-07-20

Lead Sponsor: MedImmune LLC

Target Recruit Count: 116

Registration Number: NCT00767416

Locations: 🇵🇷
Research Site, Caguas, Puerto Rico

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

Phase 2

Completed

Conditions: Asthma

Interventions: Biological: Benralizumab
Other: Placebo

First Posted Date: 2008-10-07

Last Posted Date: 2020-11-18

Lead Sponsor: MedImmune LLC

Target Recruit Count: 110

Registration Number: NCT00768079

Locations: 🇨🇦
Research Site, Halifax, Nova Scotia, Canada

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: MEDI-534, Cohort 2
Other: Placebo, Cohort 2
Biological: MEDI-534, Cohort 4
Other: Placebo, Cohort 1
Biological: MEDI-534, Cohort 3
Other: Placebo, Cohort 3
Biological: MEDI-534, Cohort 5
Biological: MEDI-534, Cohort 1
Other: Placebo, Cohort 4
Other: Placebo, Cohort 5

First Posted Date: 2008-05-29

Last Posted Date: 2014-09-26

Lead Sponsor: MedImmune LLC

Target Recruit Count: 1338

Registration Number: NCT00686075

Locations: 🇪🇸
Research Site, Valencia, Spain

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Trivalent influenza virus vaccine
Biological: Placebo

First Posted Date: 2008-05-15

Last Posted Date: 2010-10-22

Lead Sponsor: MedImmune LLC

Target Recruit Count: 300

Registration Number: NCT00677820

Locations: 🇺🇸
Covance, Austin, Austin, Texas, United States
🇺🇸
Covance, Daytona Beach, Daytona Beach, Florida, United States
🇺🇸
Covance, Portland, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy